120 related articles for article (PubMed ID: 27496215)
1. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.
Scott EC; Hari P; Sharma M; Le-Rademacher J; Huang J; Vogl D; Abidi M; Beitinjaneh A; Fung H; Ganguly S; Hildebrandt G; Holmberg L; Kalaycio M; Kumar S; Kyle R; Lazarus H; Lee C; Maziarz RT; Meehan K; Mikhael J; Nishihori T; Ramanathan M; Usmani S; Tay J; Vesole D; Wirk B; Yared J; Savani BN; Gasparetto C; Krishnan A; Mark T; Nieto Y; D'Souza A
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1893-1899. PubMed ID: 27496215
[TBL] [Abstract][Full Text] [Related]
2. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience.
Pasvolsky O; Gaballa MR; Milton DR; Masood A; Sami SS; Tanner MR; Bashir Q; Srour S; Saini N; Ramdial J; Nieto Y; Tang G; Lin P; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Transplant Cell Ther; 2023 Apr; 29(4):260.e1-260.e6. PubMed ID: 36646323
[TBL] [Abstract][Full Text] [Related]
3. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation.
Pasvolsky O; Pasyar S; Bassett RL; Khan HN; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Cancer; 2024 May; 130(9):1663-1672. PubMed ID: 38127583
[TBL] [Abstract][Full Text] [Related]
4. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.
Bock F; Lu G; Srour SA; Gaballa S; Lin HY; Baladandayuthapani V; Honhar M; Stich M; Shah ND; Bashir Q; Patel K; Popat U; Hosing C; Korbling M; Delgado R; Rondon G; Shah JJ; Thomas SK; Manasanch EE; Isermann B; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2159-2164. PubMed ID: 27638366
[TBL] [Abstract][Full Text] [Related]
5. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation.
Pasvolsky O; Wang Z; Milton DR; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Tang G; Kebriaei P; Aljawai Y; Khan HN; Lee HC; Ye C; Patel KK; Thomas SK; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Blood Cancer J; 2024 May; 14(1):82. PubMed ID: 38760362
[TBL] [Abstract][Full Text] [Related]
6. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.
Casulo C; Friedberg JW; Ahn KW; Flowers C; DiGilio A; Smith SM; Ahmed S; Inwards D; Aljurf M; Chen AI; Choe H; Cohen J; Copelan E; Farooq U; Fenske TS; Freytes C; Gaballa S; Ganguly S; Jethava Y; Kamble RT; Kenkre VP; Lazarus H; Lazaryan A; Olsson RF; Rezvani AR; Rizzieri D; Seo S; Shah GL; Shah N; Solh M; Sureda A; William B; Cumpston A; Zelenetz AD; Link BK; Hamadani M
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1163-1171. PubMed ID: 29242111
[TBL] [Abstract][Full Text] [Related]
7. Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma.
Goldman-Mazur S; Visram A; Rajkumar SV; Kapoor P; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Dingli D; Kourelis T; Gonsalves W; Warsame R; Muchtar E; Leung N; Kyle RA; Kumar SK
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e104-e111.e1. PubMed ID: 38135634
[TBL] [Abstract][Full Text] [Related]
8. Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma.
Uryu H; Mishima Y; Ishihara Y; Shirouchi Y; Yamauchi N; Hirano M; Hirano K; Teramoto Y; Yoshida K; Maruyama D
J Clin Exp Hematop; 2024; 64(1):10-20. PubMed ID: 38538316
[TBL] [Abstract][Full Text] [Related]
9. Utilization of Autologous Hematopoietic Cell Transplantation Over Time in Multiple Myeloma: A Population-Based Study.
Esteghamat NS; Brunson A; Rosenberg AS; Schonfeld SJ; Valcarcel B; Abrahão R; Cooley JJP; Meyer CL; Auletta JJ; Morton LM; Muffly L; Wun T; Keegan THM
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e119-e129. PubMed ID: 38195324
[TBL] [Abstract][Full Text] [Related]
10. Early M-protein immune reconstitution after autologous haematopoietic stem cell transplantation is a good prognostic marker for patients with high-risk cytogenetic multiple myeloma.
Zhu H; Liu J; Gu J; Chen M; Kuang L; Huang B; Zou W; Li J
Br J Haematol; 2024 Mar; 204(3):976-987. PubMed ID: 38246862
[TBL] [Abstract][Full Text] [Related]
11. The impact of social vulnerability index on survival following autologous stem cell transplant for multiple myeloma.
Salafian K; Mazimba C; Volodin L; Varadarajan I; Pilehvari A; You W; Knio ZO; Ballen K
Bone Marrow Transplant; 2024 Apr; 59(4):459-465. PubMed ID: 38238453
[TBL] [Abstract][Full Text] [Related]
12. Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis.
Derman BA; Jasielec J; Langerman SS; Zhang W; Jakubowiak AJ; Chiu BC
Blood Cancer J; 2020 Aug; 10(8):80. PubMed ID: 32770051
[TBL] [Abstract][Full Text] [Related]
13. Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study.
D'Souza A; Pasquini M; Logan B; Giralt S; Krishnan A; Antin J; Howard A; Goodman S; Qazilbash M; Knust K; Sahebi F; Weisdorf D; Vesole D; Stadtmauer E; Maloney D; Hari P
Br J Haematol; 2017 Sep; 178(5):816-819. PubMed ID: 27292583
[No Abstract] [Full Text] [Related]
14. Symptom clusters and their impact on quality of life in multiple myeloma survivors: Secondary analysis of BMT CTN 0702 trial.
Brazauskas R; Flynn K; Krishnan A; Landau H; Giralt S; Pasquini MC; Stadtmauer EA; D'Souza A
Br J Haematol; 2024 Apr; 204(4):1429-1438. PubMed ID: 38348544
[TBL] [Abstract][Full Text] [Related]
15. Individualized dynamic risk assessment for multiple myeloma.
Murie C; Turkarslan S; Patel A; Coffey DG; Becker PS; Baliga NS
medRxiv; 2024 Apr; ():. PubMed ID: 38633807
[TBL] [Abstract][Full Text] [Related]
16. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.
Cornell RF; D'Souza A; Kassim AA; Costa LJ; Innis-Shelton RD; Zhang MJ; Huang J; Abidi M; Aiello J; Akpek G; Bashey A; Bashir Q; Cerny J; Comenzo R; Diaz MA; Freytes C; Gale RP; Ganguly S; Hamadani M; Hashmi S; Holmberg L; Hossain N; Kamble RT; Kharfan-Dabaja M; Kindwall-Keller T; Kyle R; Kumar S; Lazarus H; Lee C; Maiolino A; Marks DI; Meehan K; Mikhael J; Nath R; Nishihori T; Olsson RF; Ramanathan M; Saad A; Seo S; Usmani S; Vesole D; Vij R; Vogl D; Wirk BM; Yared J; Krishnan A; Mark T; Nieto Y; Hari P
Biol Blood Marrow Transplant; 2017 Feb; 23(2):269-277. PubMed ID: 27864161
[TBL] [Abstract][Full Text] [Related]
17. Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study.
Garderet L; Beohou E; Caillot D; Stoppa AM; Touzeau C; Chretien ML; Karlin L; Moreau P; Fontan J; Blaise D; Polge E; Gueye MS; Ikhlef S; Marjanovic Z; Labopin M; Mohty M
Haematologica; 2016 Nov; 101(11):1390-1397. PubMed ID: 27612987
[TBL] [Abstract][Full Text] [Related]
18. Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice.
Lee HS; Min CK
Korean J Intern Med; 2016 Sep; 31(5):809-19. PubMed ID: 27604793
[TBL] [Abstract][Full Text] [Related]
19. A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.
Biran N; Rowley SD; Vesole DH; Zhang S; Donato ML; Richter J; Skarbnik AP; Pecora A; Siegel DS
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2165-2171. PubMed ID: 27590107
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
